Image

Global Adrenergic Bronchodilator Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Adrenergic Bronchodilator Market, By Application (Asthma, Chronic obstructive pulmonary disease (COPD), Allergic Reactions, Breathing Problem, Others), Mode of Action (Short-Acting Bronchodilators, Long-Acting Bronchodilators), Dosage (Tablets, Sprays, Injectables, Others), Route Of Administration (Inhalation, Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.

Adrenergic Bronchodilator Market

Global Adrenergic Bronchodilator Market Analysis and Size

In recent years, the adrenergic bronchodilator market is anticipated to grow rapidly during the forecast period. Respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma are more common among the elderly. According to the Centers for Disease Control and Prevention (CDC), approximately 4,069,278 Americans over the age of 65 had asthma in 2019. Because bronchodilators are essential for maintaining normal airflow in these patients' lungs, demand for bronchodilators is expected to rise in the near future.

  • Data Bridge Market Research analyses that the adrenergic bronchodilator market was valued at USD 2,006.2 million in 2021 and is expected to reach USD 3,009.6 million by 2029, registering a CAGR of 5.20% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Global Adrenergic Bronchodilator Market Definition

Adrenergic bronchodilators referred to the drugs that open up the airways. Asthma and chronic bronchitis are treated with them. Overdosing on an adrenergic bronchodilator happens when someone consumes more than the regular or recommended dose of this medication. This could happen by chance or on intent. Adrenergic bronchodilators are also termed as inhaled drugs.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Application (Asthma, Chronic obstructive pulmonary disease (COPD), Allergic Reactions, Breathing Problem, Others), Mode of Action (Short-Acting Bronchodilators, Long-Acting Bronchodilators), Dosage (Tablets, Sprays, Injectables, Others), Route Of Administration (Inhalation, Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

AstraZeneca (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Boehringer Ingelheim International GmbH. (Germany), Sun Pharmaceutical Industries Ltd. (Mumbai), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Amneal Pharmaceuticals LLC. (US), Oak Pharmaceuticals, Inc. (US), Sunovion Pharmaceuticals Inc. (US), Sanofi (France), Novartis AG (Switzerland), Abbott (US), Gilead Sciences, Inc. (US), Merck & Co., Inc. (US), Neopharm Group (US), Pieris Pharmaceuticals, Inc (US), Pharmaxis Ltd (Australia), Century Pharmaceuticals Ltd. (India)

Market Opportunities

 

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Adrenergic Bronchodilator Market Dynamics

Drivers

  • Increasing Prevalence of Pulmonary Diseases

The rising prevalence of pulmonary diseases is a primary driver of the adrenergic bronchodilator market's growth.  

  • Increasing Investment for Healthcare Infrastructure

Another significant factor influencing the growth rate of adrenergic bronchodilator market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the adrenergic bronchodilator market. Additionally, high disposable income and increasing level of government funding will result in the expansion of adrenergic bronchodilator market. Along with this, rising geriatric population and surging prevalence of chronic respiratory diseases will enhance the growth rate of the market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the adrenergic bronchodilator market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the adrenergic bronchodilator market growth during the forecast period.

Restraints/Challenges Global Adrenergic Bronchodilator Market

On the other hand, the high cost associated with the adrenergic bronchodilator will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the adrenergic bronchodilator market. Additionally, strict guidelines as well as regulations and side effects linked with adrenergic bronchodilator such as pain, dizziness, muscle twitching, weakness, vomiting and others will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This adrenergic bronchodilator market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the adrenergic bronchodilator market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Adrenergic bronchodilator market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Adrenergic Bronchodilator Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. A significant increase in the number of individuals with respiratory illnesses as a result of COVID-19 is expected to increase global demand for bronchodilators. Several studies suggest that using bronchodilator drugs to treat COVID-19 patients can help patients breathe more normally and enhance their functional abilities. These drugs are most effective in COVID-19 instances with reactive airway illnesses that have been verified or suspected. However, several studies contradict the efficacy of bronchodilators, concluding that no substantial changes are detected in affected patients, with very minor improvements in clinical outcomes for lowering mortality risk. As a result, the pandemic is expected to have a moderate impact on the adrenergic bronchodilator market.

Global Adrenergic Bronchodilator Market Scope

The adrenergic bronchodilator market is segmented on the basis of mode of action, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Mode of Action

  • Short-Acting Bronchodilators
  • Long-Acting Bronchodilators

On the basis of mode of action, the global adrenergic bronchodilatormarket is segmented into short-acting bronchodilators, and long-acting bronchodilators.

Application

  • Asthma
  • Chronic obstructive pulmonary disease (COPD)
  • Allergic Reactions
  • Breathing Problem
  • Others

On the basis of application, the global adrenergic bronchodilatormarket is segmented into asthma, chronic obstructive pulmonary disease (COPD), allergic reactions, breathing problem and others. 

Dosage

  • Tablets
  • Sprays
  • Injectables
  • Others

On the basis of dosage, the adrenergic bronchodilator market is segmented into tablets, sprays, injectables and others.  

Route of Administration

  • Inhalation
  • Oral
  • Parenteral

The route of administration segment for the adrenergic bronchodilator market is segmented into inhalation, oral, and parenteral.

 End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

On the basis of end-users, the adrenergic bronchodilator market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

On the basis of distribution channel, the adrenergic bronchodilator market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Adrenergic Bronchodilator Market Regional Analysis/Insights

The Adrenergic bronchodilator market is analysed and market size insights and trends are provided by country, mode of action, application, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the adrenergic bronchodilator market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the adrenergic bronchodilator market because of the growing number of patients suffering from asthma and growing adoption of inhaled therapeutics in this region. Additionally, growing presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to rising healthcare expenditure and rising number of people suffering from asthma and others respiratory diseases in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Adrenergic Bronchodilator Market Share Analysis

The Adrenergic bronchodilator market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to adrenergic bronchodilator market.

Some of the major players operating in the adrenergic bronchodilator market are:

  • AstraZeneca (UK)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Jerusalem)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Sun Pharmaceutical Industries Ltd. (Mumbai)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Amneal Pharmaceuticals LLC. (US)
  • Oak Pharmaceuticals, Inc. (US)
  • Sunovion Pharmaceuticals Inc. (US)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Abbott (US)
  • Gilead Sciences, Inc. (US)
  • Merck & Co., Inc. (US)
  • Neopharm Group (US)
  • Pieris Pharmaceuticals, Inc (US)
  • Pharmaxis Ltd (Australia)
  • Century Pharmaceuticals Ltd. (India)    

Research Methodology : Global Adrenergic Bronchodilator Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available : Global Adrenergic Bronchodilator Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The Market Value for Adrenergic Bronchodilator Market is expected USD 3,009.6 million by 2029.
The Adrenergic Bronchodilator Market is to Grow at a CAGR of 5.20% During the Forecast Period of 2022 to 2029.
AstraZeneca (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Boehringer Ingelheim International GmbH. (Germany), Sun Pharmaceutical Industries Ltd. (Mumbai), Pfizer Inc. (US), Pharmaxis Ltd (Australia), Century Pharmaceuticals Ltd. (India) are the Major Companies Operating in Adrenergic Bronchodilator Market.
The Countries Covered in the Adrenergic Bronchodilator Market Report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
The Adrenergic Bronchodilator Market Report Curated by the Data Bridge Market Research Team Includes In-Depth Expert Analysis, Patient Epidemiology, Pipeline Analysis, Pricing Analysis, and Regulatory Framework.